{
  "id": 7785952,
  "title": "Integrative pipeline to profile and target endocrine therapy-insensitive cell populations in ER+ breast cancer",
  "url": "https://urgent.news/2026/09/16/integrative-pipeline-to-profile-and-target-endocrine-therapy",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-16T00:00:00.000Z",
  "source": {
    "name": "bioRxiv",
    "slug": "biorxiv",
    "url": "https://www.biorxiv.org/content/10.64898/2026.09.10.750719v1?rss=1"
  },
  "original_language": "en",
  "account": null,
  "summary": "Up to 40% of patients with estrogen receptor positive breast cancer will experience relapse, either while on endocrine therapy (ET) or after ET is completed. A major contributor to ET failure is the presence of ET-insensitive cell populations within tumors. Here, we developed an analytical pipeline to systematically identify and target these populations by integrating single-cell RNA sequencing…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}